Victory Capital Management Inc. Raises Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Victory Capital Management Inc. increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 25.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 467,577 shares of the medical research company's stock after acquiring an additional 93,849 shares during the quarter. Victory Capital Management Inc. owned about 0.91% of Charles River Laboratories International worth $110,535,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Cardinal Capital Management raised its position in shares of Charles River Laboratories International by 0.6% in the 4th quarter. Cardinal Capital Management now owns 8,450 shares of the medical research company's stock worth $1,998,000 after acquiring an additional 47 shares in the last quarter. Massmutual Trust Co. FSB ADV increased its holdings in Charles River Laboratories International by 21.5% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 328 shares of the medical research company's stock worth $78,000 after purchasing an additional 58 shares in the last quarter. Patriot Financial Group Insurance Agency LLC lifted its stake in Charles River Laboratories International by 5.7% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 1,126 shares of the medical research company's stock valued at $266,000 after buying an additional 61 shares during the period. Advisor Partners II LLC boosted its holdings in shares of Charles River Laboratories International by 2.7% during the 3rd quarter. Advisor Partners II LLC now owns 2,393 shares of the medical research company's stock worth $469,000 after buying an additional 63 shares in the last quarter. Finally, M&T Bank Corp boosted its holdings in shares of Charles River Laboratories International by 3.3% during the 3rd quarter. M&T Bank Corp now owns 2,076 shares of the medical research company's stock worth $407,000 after buying an additional 66 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Insiders Place Their Bets

In related news, VP William D. Barbo sold 4,050 shares of the stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the transaction, the vice president now owns 22,879 shares in the company, valued at $5,685,431.50. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Charles River Laboratories International news, EVP Victoria L. Creamer sold 5,000 shares of the business's stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the sale, the executive vice president now directly owns 13,550 shares in the company, valued at $3,437,635. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP William D. Barbo sold 4,050 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total value of $1,006,425.00. Following the transaction, the vice president now owns 22,879 shares of the company's stock, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,932 shares of company stock valued at $3,693,663. Insiders own 1.30% of the company's stock.

Analyst Upgrades and Downgrades

CRL has been the topic of a number of research reports. TheStreet upgraded shares of Charles River Laboratories International from a "c+" rating to a "b-" rating in a research report on Friday, March 1st. Evercore ISI increased their price objective on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the stock an "outperform" rating in a research report on Thursday, February 15th. Argus boosted their target price on Charles River Laboratories International from $240.00 to $290.00 and gave the company a "buy" rating in a research report on Monday, March 18th. Citigroup increased their price target on Charles River Laboratories International from $215.00 to $250.00 and gave the stock a "neutral" rating in a report on Thursday, February 15th. Finally, UBS Group boosted their price objective on Charles River Laboratories International from $270.00 to $290.00 and gave the company a "buy" rating in a report on Thursday, February 15th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $253.23.

Charles River Laboratories International Stock Up 1.6 %

Shares of NYSE CRL traded up $3.58 during trading on Friday, hitting $233.47. The stock had a trading volume of 466,192 shares, compared to its average volume of 545,276. The firm has a fifty day moving average of $252.52 and a two-hundred day moving average of $223.69. The company has a market capitalization of $12.03 billion, a PE ratio of 24.96, a PEG ratio of 1.82 and a beta of 1.44. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16. Charles River Laboratories International, Inc. has a 12 month low of $161.65 and a 12 month high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $991.25 million. During the same period in the prior year, the firm posted $2.98 EPS. The firm's quarterly revenue was down 7.9% compared to the same quarter last year. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).